BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
Oct 3, 2025 • 13min
Brian Alexander, former CEO of Foundation Medicine, describes how Valo Health is using its AI expertise to partner with companies and foundations on discovery and development projects
The company recently received a grant from the Michael J. Fox Foundation to work on Parkinson's, and has existing partnerships with companies such as Novo and Charles River.
Oct 1, 2025 • 13min
Aerska launched in the UK today with $21M in financing to develop RNAi medicines for neurological conditions that are delivered to the brain via 'brain shuttle' technologies across the BBB
Chief Executive Officer Jack O'Meara, who previously founded Ochre Bio in the RNA space, describes the potential benefits of using brain shuttles and why the time is right for this approach. Plus, the company's business model and what to expect next.
Sep 29, 2025 • 22min
Enanta Pharmaceuticals' CEO and CMO discuss data announced today on the company's RSV treatment, Zelicapavir, and describe the road ahead for this program and the company
CEO Jay Luly and CMO Scott Rottinghaus describe today's data, which was focused on high risk adults. They explain how safety and efficacy were measured, and what the learnings were from a handful of endpoints. Plus, Enanta's earlier stage I&I programs targeting KIT and STAT6.
Sep 26, 2025 • 15min
Sunny Kumar, a partner at Informed Ventures, and an active investor in the AI space, talks about current and future implications of AI's impact on healthcare
He discussed how current technologies are making healthcare more effecient today, how new technologies are opening new markets, and how the practice of medicine might be changed in the process.
Sep 19, 2025 • 10min
Eko Health's Co-Founder & CEO shows BiotechTV the company's digital stethoscope and explains how having both an electric and sound component can help physicians catch heart disease (and more) earlier
Connor Landgraf shows us the product and describes recent data the company compiled in the UK showing the benefits of using this digital and AI enhanced device over a traditional stethoscope.
Sep 18, 2025 • 13min
Sweden's Annoca announced a $46M raise last month to help move its first TCR-T program into the clinic for KRAS-driven pancreatic cancer. CEO Reagan Jarvis tells us about that work and more.
He describes the raise and the trial, which is an umbrella study that will test products against three different mutations. Plus, work on vaccines and a non-oncology cell therapy program, and partnership opportunities.
Sep 17, 2025 • 16min
Xspray Pharma makes protein kinase inhibitors that are amorphous, and therefore more soluble than current products. Dasynoc, its version of dasatinib (Sprycel), is in front of FDA with an Oct 7 PDUFA
CEO Per Andersson walks us through the benefits of designing kinase inhibitors this way, which should not be affected by the pH of the stomach. He shows us the unique manufacturing equipment, and walks us through a pipeline that includes dasatinib, nilotinib, axitinib, and cabozantinib.
Sep 16, 2025 • 9min
Pareto Securities Healthcare Conference: Egetis Therapeutics has a therapy for a rare disease called MCT8 deficiency that is approved by the EMA and has breakthrough therapy designation in the U.S.
CEO Nicklas Westerholm walks us through the condition, which is an X-chromosome linked rare disease that affects men, and he describes how the launch is going in Europe, and plans for an FDA meeting.
Sep 16, 2025 • 9min
Pareto Securities' Healthcare Conference: Cinclus Pharma is trying to user in the next generation of acid reflux medicines with, linaprazan glurate, a potassium-competitive acid blocker (P-CAB)
CEO Christer Ahlberg describes the shortcomings of today's medicines, and why he believes a P-CAB is the answer. This therapy originated at AstraZeneca, though Cinclus owns it outright today, and is in a phase 3 that just started.
Sep 16, 2025 • 11min
Pareto Securities' Healthcare Conference: Biotech Analyst Dan Akschuti shares his take on the the conference and the state of biotech, and highlights key companies to watch in the region
He sees an optimistic turn after a challenging couple of years. Plus, highlighting Vicor, Camurus, Oculis, and BioArctic.
